Mazdutide 9 mg in Chinese adults with a body mass index ≥30 kg/m2 but without diabetes: A phase 2 randomized controlled trial - PubMed
4 hours ago
- #weight-loss
- #obesity
- #clinical-trial
- Mazdutide 9 mg was tested in a phase 2 randomized controlled trial on Chinese adults with BMI ≥30 kg/m² without diabetes.
- The study showed a mean weight reduction of -12.78% with mazdutide 9 mg compared to 1.80% with placebo after 24 weeks.
- 81.7% of participants on mazdutide achieved ≥5% weight loss, while none in the placebo group did.
- Mazdutide improved cardiometabolic risk factors but had common side effects like nausea (50%), diarrhea (38.3%), and vomiting (36.7%).
- The trial concluded that mazdutide 9 mg is safe and effective for weight loss in obese Chinese adults without diabetes.